| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Berylliosis | 78 | 2026 | 202 | 14.420 |
Why?
|
| Sarcoidosis | 43 | 2026 | 163 | 9.490 |
Why?
|
| Beryllium | 61 | 2025 | 161 | 9.460 |
Why?
|
| Sarcoidosis, Pulmonary | 31 | 2026 | 97 | 9.060 |
Why?
|
| Occupational Exposure | 39 | 2025 | 354 | 5.810 |
Why?
|
| HLA-DP beta-Chains | 15 | 2025 | 87 | 2.980 |
Why?
|
| Occupational Diseases | 9 | 2025 | 165 | 2.530 |
Why?
|
| Gastrointestinal Microbiome | 12 | 2025 | 772 | 2.430 |
Why?
|
| Bacteria | 13 | 2025 | 891 | 2.330 |
Why?
|
| Bronchoalveolar Lavage Fluid | 28 | 2026 | 636 | 2.310 |
Why?
|
| Genetic Predisposition to Disease | 19 | 2026 | 2371 | 1.900 |
Why?
|
| Salmonella typhimurium | 7 | 2025 | 190 | 1.900 |
Why?
|
| Microbiota | 9 | 2025 | 781 | 1.800 |
Why?
|
| Chronic Disease | 49 | 2022 | 1814 | 1.680 |
Why?
|
| Lung Diseases | 10 | 2022 | 790 | 1.650 |
Why?
|
| Lung | 36 | 2026 | 4112 | 1.620 |
Why?
|
| Biomarkers | 16 | 2026 | 4284 | 1.490 |
Why?
|
| Polymorphism, Genetic | 13 | 2021 | 612 | 1.330 |
Why?
|
| Humans | 193 | 2026 | 145307 | 1.310 |
Why?
|
| Tomography, X-Ray Computed | 11 | 2026 | 2745 | 1.300 |
Why?
|
| Symbiosis | 4 | 2025 | 81 | 1.280 |
Why?
|
| Bacteria, Anaerobic | 3 | 2025 | 25 | 1.260 |
Why?
|
| Adrenal Cortex Hormones | 5 | 2020 | 480 | 1.200 |
Why?
|
| CD4-Positive T-Lymphocytes | 20 | 2026 | 1130 | 1.150 |
Why?
|
| HLA-DP Antigens | 9 | 2011 | 32 | 1.080 |
Why?
|
| Leukocytes, Mononuclear | 9 | 2026 | 573 | 1.060 |
Why?
|
| Lymphocytes | 13 | 2020 | 382 | 1.040 |
Why?
|
| Environmental Exposure | 8 | 2026 | 594 | 1.030 |
Why?
|
| Pulmonary Fibrosis | 4 | 2026 | 395 | 1.000 |
Why?
|
| Middle Aged | 84 | 2026 | 36021 | 0.990 |
Why?
|
| HLA-DRB1 Chains | 4 | 2025 | 109 | 0.990 |
Why?
|
| Proteomics | 8 | 2026 | 1195 | 0.980 |
Why?
|
| Case-Control Studies | 25 | 2024 | 3613 | 0.940 |
Why?
|
| Male | 101 | 2026 | 72629 | 0.920 |
Why?
|
| Anti-Bacterial Agents | 10 | 2025 | 1922 | 0.900 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 5 | 2022 | 923 | 0.890 |
Why?
|
| Biotechnology | 1 | 2025 | 46 | 0.870 |
Why?
|
| Female | 98 | 2026 | 78605 | 0.850 |
Why?
|
| Clostridium Infections | 1 | 2025 | 74 | 0.840 |
Why?
|
| Proton Pump Inhibitors | 1 | 2025 | 109 | 0.840 |
Why?
|
| Tumor Necrosis Factor-alpha | 14 | 2021 | 1217 | 0.840 |
Why?
|
| Immunoglobulin E | 1 | 2026 | 315 | 0.830 |
Why?
|
| Alleles | 12 | 2025 | 881 | 0.830 |
Why?
|
| High-Throughput Screening Assays | 2 | 2023 | 175 | 0.820 |
Why?
|
| Granuloma | 7 | 2024 | 96 | 0.810 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2017 | 338 | 0.800 |
Why?
|
| Food Hypersensitivity | 1 | 2026 | 164 | 0.800 |
Why?
|
| Gastrointestinal Tract | 3 | 2014 | 208 | 0.790 |
Why?
|
| Gene Expression Regulation | 6 | 2021 | 2609 | 0.780 |
Why?
|
| Genotype | 16 | 2025 | 1845 | 0.780 |
Why?
|
| Gene-Environment Interaction | 2 | 2026 | 182 | 0.770 |
Why?
|
| Feces | 7 | 2025 | 514 | 0.760 |
Why?
|
| Alveolitis, Extrinsic Allergic | 6 | 2021 | 93 | 0.760 |
Why?
|
| Adult | 67 | 2026 | 40627 | 0.750 |
Why?
|
| Skin Diseases | 2 | 2024 | 149 | 0.740 |
Why?
|
| Lipopolysaccharide Receptors | 3 | 2015 | 87 | 0.740 |
Why?
|
| Nicotine | 2 | 2021 | 332 | 0.740 |
Why?
|
| Phenotype | 13 | 2026 | 3173 | 0.730 |
Why?
|
| Bacterial Infections | 1 | 2024 | 246 | 0.710 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2025 | 199 | 0.690 |
Why?
|
| Disease Progression | 10 | 2026 | 2855 | 0.690 |
Why?
|
| Pulmonary Diffusing Capacity | 4 | 2026 | 78 | 0.680 |
Why?
|
| Lymphocyte Activation | 18 | 2014 | 1127 | 0.670 |
Why?
|
| Hypersensitivity | 6 | 2014 | 253 | 0.650 |
Why?
|
| DNA Methylation | 4 | 2025 | 686 | 0.620 |
Why?
|
| HLA Antigens | 3 | 2015 | 232 | 0.610 |
Why?
|
| Mesalamine | 2 | 2017 | 9 | 0.610 |
Why?
|
| Aged | 48 | 2025 | 26001 | 0.610 |
Why?
|
| Drug Interactions | 1 | 2021 | 401 | 0.600 |
Why?
|
| Receptors, IgG | 2 | 2018 | 76 | 0.570 |
Why?
|
| Biomedical Research | 4 | 2022 | 713 | 0.570 |
Why?
|
| Respiratory Hypersensitivity | 5 | 2012 | 65 | 0.560 |
Why?
|
| Ecosystem | 1 | 2023 | 590 | 0.560 |
Why?
|
| Immunity, Cellular | 2 | 2017 | 273 | 0.550 |
Why?
|
| Respiratory Function Tests | 10 | 2026 | 547 | 0.540 |
Why?
|
| Genome-Wide Association Study | 8 | 2026 | 1414 | 0.530 |
Why?
|
| Cytokines | 8 | 2019 | 2066 | 0.520 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 194 | 0.510 |
Why?
|
| Dyspnea | 2 | 2021 | 251 | 0.510 |
Why?
|
| Cough | 1 | 2018 | 124 | 0.500 |
Why?
|
| Longitudinal Studies | 9 | 2026 | 2959 | 0.490 |
Why?
|
| Asthma | 3 | 2020 | 1776 | 0.490 |
Why?
|
| Gene Expression Profiling | 3 | 2021 | 1787 | 0.480 |
Why?
|
| Cell Proliferation | 13 | 2018 | 2506 | 0.470 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 3 | 2022 | 59 | 0.470 |
Why?
|
| Host-Pathogen Interactions | 5 | 2024 | 371 | 0.470 |
Why?
|
| Macrophages, Alveolar | 4 | 2020 | 368 | 0.460 |
Why?
|
| Military Personnel | 1 | 2024 | 747 | 0.460 |
Why?
|
| Proteins | 3 | 2020 | 1026 | 0.460 |
Why?
|
| Spirometry | 3 | 2026 | 231 | 0.460 |
Why?
|
| Transcriptome | 5 | 2026 | 1046 | 0.450 |
Why?
|
| Bronchoalveolar Lavage | 6 | 2022 | 89 | 0.450 |
Why?
|
| Radiography, Thoracic | 4 | 2026 | 171 | 0.450 |
Why?
|
| Immunization | 4 | 2008 | 374 | 0.440 |
Why?
|
| Granulocytes | 1 | 2014 | 80 | 0.430 |
Why?
|
| Hydrogenase | 1 | 2014 | 12 | 0.430 |
Why?
|
| Animals | 31 | 2026 | 38180 | 0.430 |
Why?
|
| Salmonella Infections, Animal | 1 | 2014 | 39 | 0.430 |
Why?
|
| Anaerobiosis | 2 | 2025 | 64 | 0.420 |
Why?
|
| Salmonella Infections | 4 | 2025 | 60 | 0.420 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2026 | 2152 | 0.410 |
Why?
|
| Severity of Illness Index | 11 | 2024 | 2926 | 0.410 |
Why?
|
| Mycophenolic Acid | 1 | 2014 | 120 | 0.410 |
Why?
|
| Chemokine CCL3 | 2 | 2026 | 26 | 0.410 |
Why?
|
| Particle Size | 4 | 2014 | 412 | 0.400 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2014 | 266 | 0.400 |
Why?
|
| Dendritic Cells | 3 | 2026 | 499 | 0.400 |
Why?
|
| Occupational Health | 3 | 2025 | 210 | 0.390 |
Why?
|
| Immunity, Innate | 4 | 2022 | 846 | 0.390 |
Why?
|
| Models, Immunological | 3 | 2013 | 100 | 0.390 |
Why?
|
| Mice | 19 | 2026 | 18397 | 0.380 |
Why?
|
| Allergens | 4 | 2012 | 386 | 0.380 |
Why?
|
| Odds Ratio | 6 | 2020 | 1077 | 0.370 |
Why?
|
| Periodicals as Topic | 1 | 2015 | 204 | 0.360 |
Why?
|
| T-Lymphocytes | 4 | 2022 | 1984 | 0.360 |
Why?
|
| Cardiomyopathies | 5 | 2020 | 338 | 0.360 |
Why?
|
| Risk Factors | 16 | 2026 | 10816 | 0.360 |
Why?
|
| Escherichia coli | 4 | 2025 | 855 | 0.350 |
Why?
|
| Immunosuppressive Agents | 3 | 2024 | 847 | 0.350 |
Why?
|
| Air Pollutants, Occupational | 2 | 2010 | 42 | 0.350 |
Why?
|
| Colitis | 1 | 2014 | 280 | 0.350 |
Why?
|
| Mandibular Fractures | 2 | 2022 | 14 | 0.350 |
Why?
|
| Glutamic Acid | 4 | 2007 | 251 | 0.340 |
Why?
|
| Diagnosis, Differential | 6 | 2024 | 1500 | 0.340 |
Why?
|
| Medical Laboratory Personnel | 1 | 2010 | 6 | 0.320 |
Why?
|
| Mandibular Nerve | 2 | 2020 | 5 | 0.320 |
Why?
|
| Forced Expiratory Volume | 4 | 2018 | 449 | 0.320 |
Why?
|
| Pulmonary Emphysema | 2 | 2023 | 275 | 0.320 |
Why?
|
| Endotoxins | 2 | 2010 | 221 | 0.310 |
Why?
|
| Vital Capacity | 4 | 2019 | 290 | 0.310 |
Why?
|
| Receptors, CCR5 | 1 | 2010 | 60 | 0.300 |
Why?
|
| Quality of Life | 8 | 2024 | 3197 | 0.300 |
Why?
|
| Th1 Cells | 3 | 2013 | 139 | 0.300 |
Why?
|
| Antibodies, Monoclonal | 5 | 2012 | 1525 | 0.300 |
Why?
|
| Smoking | 6 | 2021 | 1472 | 0.290 |
Why?
|
| Aged, 80 and over | 16 | 2025 | 8295 | 0.290 |
Why?
|
| Systems Biology | 2 | 2021 | 72 | 0.280 |
Why?
|
| United States | 15 | 2025 | 16051 | 0.280 |
Why?
|
| Lung Diseases, Interstitial | 2 | 2020 | 660 | 0.280 |
Why?
|
| Interferon-gamma | 8 | 2021 | 784 | 0.280 |
Why?
|
| HLA-DR Antigens | 4 | 2015 | 220 | 0.280 |
Why?
|
| Klebsiella pneumoniae | 2 | 2025 | 47 | 0.270 |
Why?
|
| Exosomes | 2 | 2021 | 104 | 0.270 |
Why?
|
| Logistic Models | 7 | 2020 | 2119 | 0.270 |
Why?
|
| Glutathione | 3 | 2017 | 375 | 0.270 |
Why?
|
| Administration, Inhalation | 2 | 2020 | 575 | 0.270 |
Why?
|
| RNA | 3 | 2023 | 940 | 0.260 |
Why?
|
| Cell Communication | 2 | 2026 | 324 | 0.250 |
Why?
|
| Multicenter Studies as Topic | 2 | 2026 | 411 | 0.250 |
Why?
|
| Cohort Studies | 5 | 2026 | 5982 | 0.250 |
Why?
|
| Lipopolysaccharides | 4 | 2025 | 863 | 0.240 |
Why?
|
| Aerosols | 3 | 2026 | 188 | 0.240 |
Why?
|
| Bacterial Proteins | 3 | 2025 | 962 | 0.240 |
Why?
|
| Retrospective Studies | 10 | 2024 | 17149 | 0.240 |
Why?
|
| Epitopes, T-Lymphocyte | 3 | 2021 | 175 | 0.240 |
Why?
|
| Reactive Oxygen Species | 3 | 2025 | 622 | 0.240 |
Why?
|
| Bronchoscopy | 5 | 2021 | 227 | 0.230 |
Why?
|
| Disease Models, Animal | 6 | 2026 | 4580 | 0.230 |
Why?
|
| Mice, Inbred C57BL | 7 | 2025 | 6009 | 0.230 |
Why?
|
| Bacteroides | 2 | 2025 | 20 | 0.230 |
Why?
|
| Chemokine CCL4 | 2 | 2026 | 31 | 0.230 |
Why?
|
| Gammaproteobacteria | 1 | 2025 | 13 | 0.230 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2022 | 3888 | 0.230 |
Why?
|
| Omeprazole | 1 | 2025 | 8 | 0.230 |
Why?
|
| Sputum | 3 | 2025 | 308 | 0.230 |
Why?
|
| Research Design | 2 | 2026 | 1137 | 0.220 |
Why?
|
| T-Lymphocyte Subsets | 7 | 2013 | 415 | 0.220 |
Why?
|
| Cause of Death | 2 | 2019 | 474 | 0.220 |
Why?
|
| Macrophages | 5 | 2026 | 1514 | 0.220 |
Why?
|
| Air Pollution | 2 | 2025 | 327 | 0.220 |
Why?
|
| Mortality | 2 | 2019 | 376 | 0.220 |
Why?
|
| Bioreactors | 1 | 2025 | 50 | 0.220 |
Why?
|
| Intestines | 3 | 2025 | 358 | 0.220 |
Why?
|
| Membrane Glycoproteins | 1 | 2007 | 501 | 0.220 |
Why?
|
| Biopsy | 5 | 2020 | 1079 | 0.220 |
Why?
|
| Cluster Analysis | 2 | 2026 | 521 | 0.210 |
Why?
|
| Spiro Compounds | 1 | 2024 | 17 | 0.210 |
Why?
|
| Pyrroles | 1 | 2025 | 218 | 0.210 |
Why?
|
| Genetic Variation | 3 | 2023 | 986 | 0.210 |
Why?
|
| Central Nervous System Diseases | 2 | 2021 | 74 | 0.200 |
Why?
|
| Ketones | 1 | 2024 | 53 | 0.200 |
Why?
|
| Prognosis | 4 | 2026 | 4310 | 0.200 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2025 | 550 | 0.200 |
Why?
|
| Chemokine CX3CL1 | 1 | 2023 | 25 | 0.200 |
Why?
|
| Benzodioxoles | 1 | 2025 | 158 | 0.200 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2025 | 563 | 0.200 |
Why?
|
| Peritonitis | 1 | 2024 | 85 | 0.200 |
Why?
|
| Adolescent | 13 | 2026 | 22507 | 0.200 |
Why?
|
| Neopterin | 1 | 2003 | 13 | 0.200 |
Why?
|
| Escherichia coli Proteins | 1 | 2025 | 206 | 0.200 |
Why?
|
| Spirulina | 1 | 2023 | 4 | 0.190 |
Why?
|
| Fluorocarbons | 1 | 2025 | 143 | 0.190 |
Why?
|
| Quinolones | 1 | 2025 | 201 | 0.190 |
Why?
|
| Cysteine Proteases | 1 | 2023 | 8 | 0.190 |
Why?
|
| Environmental Pollutants | 1 | 2025 | 168 | 0.190 |
Why?
|
| Genetic Association Studies | 2 | 2023 | 373 | 0.190 |
Why?
|
| Mandible | 2 | 2020 | 72 | 0.190 |
Why?
|
| Aminophenols | 1 | 2025 | 201 | 0.190 |
Why?
|
| Metagenomics | 2 | 2023 | 182 | 0.190 |
Why?
|
| Somatomedins | 1 | 2022 | 28 | 0.190 |
Why?
|
| Alkanesulfonic Acids | 1 | 2022 | 49 | 0.180 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2003 | 364 | 0.180 |
Why?
|
| Stress, Physiological | 1 | 2025 | 453 | 0.180 |
Why?
|
| Double-Blind Method | 3 | 2017 | 2033 | 0.180 |
Why?
|
| Inhalation Exposure | 3 | 2020 | 115 | 0.180 |
Why?
|
| Dicumarol | 1 | 2021 | 3 | 0.180 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 2 | 2022 | 103 | 0.180 |
Why?
|
| Duloxetine Hydrochloride | 1 | 2021 | 10 | 0.180 |
Why?
|
| Erythromycin | 1 | 2021 | 20 | 0.180 |
Why?
|
| Cell Membrane | 1 | 2025 | 708 | 0.180 |
Why?
|
| Germ-Free Life | 1 | 2021 | 33 | 0.180 |
Why?
|
| Aspergillus nidulans | 1 | 2021 | 6 | 0.180 |
Why?
|
| Tetracyclines | 1 | 2021 | 17 | 0.170 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2025 | 370 | 0.170 |
Why?
|
| Immunologic Tests | 1 | 2001 | 15 | 0.170 |
Why?
|
| Dust | 1 | 2022 | 102 | 0.170 |
Why?
|
| Macrolides | 1 | 2021 | 69 | 0.170 |
Why?
|
| Nuclear Weapons | 2 | 2011 | 7 | 0.170 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2024 | 250 | 0.170 |
Why?
|
| T-Lymphocytes, Regulatory | 4 | 2021 | 389 | 0.170 |
Why?
|
| Hydrogen Sulfide | 1 | 2001 | 48 | 0.170 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 20 | 0.160 |
Why?
|
| Silicon Dioxide | 1 | 2022 | 121 | 0.160 |
Why?
|
| Societies | 1 | 2020 | 40 | 0.160 |
Why?
|
| Maximum Allowable Concentration | 1 | 2020 | 16 | 0.160 |
Why?
|
| Circulating MicroRNA | 1 | 2021 | 26 | 0.160 |
Why?
|
| Air Pollutants | 2 | 2025 | 439 | 0.160 |
Why?
|
| Immunoglobulin G | 4 | 2022 | 893 | 0.160 |
Why?
|
| Arthroplasty, Replacement | 1 | 2021 | 47 | 0.160 |
Why?
|
| Salmo salar | 1 | 2020 | 1 | 0.160 |
Why?
|
| Aquaculture | 1 | 2020 | 3 | 0.160 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2025 | 782 | 0.160 |
Why?
|
| Smoke | 1 | 2021 | 148 | 0.160 |
Why?
|
| Interleukin-4 | 1 | 2001 | 206 | 0.160 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 57 | 0.160 |
Why?
|
| Unemployment | 1 | 2020 | 42 | 0.160 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2020 | 80 | 0.160 |
Why?
|
| Lingual Nerve | 1 | 2019 | 1 | 0.160 |
Why?
|
| Communicable Diseases | 1 | 2022 | 163 | 0.150 |
Why?
|
| Sensitivity and Specificity | 5 | 2013 | 1992 | 0.150 |
Why?
|
| Insulin Infusion Systems | 1 | 2024 | 477 | 0.150 |
Why?
|
| Masks | 1 | 2020 | 70 | 0.150 |
Why?
|
| Microbial Interactions | 1 | 2019 | 19 | 0.150 |
Why?
|
| Extracellular Vesicles | 1 | 2022 | 171 | 0.150 |
Why?
|
| Young Adult | 11 | 2025 | 14163 | 0.150 |
Why?
|
| Retinal Artery | 1 | 2019 | 17 | 0.150 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2025 | 371 | 0.150 |
Why?
|
| Electrocardiography | 2 | 2020 | 663 | 0.150 |
Why?
|
| Inflammation Mediators | 3 | 2012 | 509 | 0.150 |
Why?
|
| Iron | 1 | 2021 | 359 | 0.150 |
Why?
|
| Eating | 1 | 2021 | 392 | 0.150 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 1999 | 56 | 0.150 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2019 | 84 | 0.140 |
Why?
|
| Pneumoconiosis | 1 | 2019 | 20 | 0.140 |
Why?
|
| Income | 1 | 2020 | 202 | 0.140 |
Why?
|
| Biological Evolution | 2 | 2013 | 489 | 0.140 |
Why?
|
| Antioxidants | 2 | 2016 | 549 | 0.140 |
Why?
|
| Immunologic Memory | 4 | 2013 | 366 | 0.140 |
Why?
|
| Kidney Diseases | 2 | 2020 | 427 | 0.140 |
Why?
|
| Regression Analysis | 3 | 2019 | 1003 | 0.140 |
Why?
|
| Propensity Score | 1 | 2020 | 370 | 0.140 |
Why?
|
| Virulence Factors | 3 | 2014 | 174 | 0.140 |
Why?
|
| Residual Volume | 1 | 2018 | 5 | 0.140 |
Why?
|
| Chemokines | 2 | 2019 | 218 | 0.140 |
Why?
|
| Gene Expression | 2 | 2021 | 1490 | 0.140 |
Why?
|
| Algorithms | 2 | 2020 | 1846 | 0.130 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2016 | 341 | 0.130 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2020 | 182 | 0.130 |
Why?
|
| Cell Division | 7 | 2025 | 766 | 0.130 |
Why?
|
| In Vitro Techniques | 2 | 2018 | 1048 | 0.130 |
Why?
|
| Metagenome | 2 | 2022 | 149 | 0.130 |
Why?
|
| Immunologic Factors | 1 | 2020 | 258 | 0.130 |
Why?
|
| Microbial Viability | 1 | 2018 | 90 | 0.130 |
Why?
|
| Cost of Illness | 1 | 2020 | 322 | 0.130 |
Why?
|
| September 11 Terrorist Attacks | 1 | 2017 | 31 | 0.130 |
Why?
|
| Monocytes | 2 | 2023 | 538 | 0.130 |
Why?
|
| Dietary Fats | 1 | 2019 | 315 | 0.130 |
Why?
|
| Dental Technicians | 2 | 2014 | 2 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 285 | 0.130 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2018 | 96 | 0.130 |
Why?
|
| Reproducibility of Results | 4 | 2021 | 3419 | 0.130 |
Why?
|
| Arthritis, Juvenile | 1 | 2017 | 58 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2024 | 3906 | 0.130 |
Why?
|
| Liver Diseases | 1 | 2020 | 305 | 0.120 |
Why?
|
| Cellular Senescence | 1 | 2019 | 228 | 0.120 |
Why?
|
| HLA-DQ Antigens | 2 | 2010 | 173 | 0.120 |
Why?
|
| Firefighters | 1 | 2017 | 47 | 0.120 |
Why?
|
| Ventricular Function, Right | 1 | 2019 | 297 | 0.120 |
Why?
|
| RNA, Ribosomal, 16S | 3 | 2025 | 559 | 0.120 |
Why?
|
| Pilot Projects | 2 | 2020 | 1894 | 0.120 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 360 | 0.120 |
Why?
|
| Congresses as Topic | 1 | 2018 | 221 | 0.120 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2019 | 361 | 0.120 |
Why?
|
| Biological Products | 1 | 2020 | 255 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 3 | 2019 | 1260 | 0.120 |
Why?
|
| Pyridines | 2 | 2025 | 605 | 0.120 |
Why?
|
| Genome, Human | 1 | 2019 | 422 | 0.120 |
Why?
|
| Banking, Personal | 1 | 2016 | 2 | 0.120 |
Why?
|
| Disease Management | 1 | 2020 | 647 | 0.120 |
Why?
|
| Positron-Emission Tomography | 2 | 2020 | 343 | 0.120 |
Why?
|
| Global Health | 2 | 2018 | 403 | 0.120 |
Why?
|
| Deoxyguanosine | 1 | 2016 | 25 | 0.120 |
Why?
|
| Lung Injury | 1 | 2019 | 239 | 0.120 |
Why?
|
| Predictive Value of Tests | 5 | 2019 | 2118 | 0.120 |
Why?
|
| Health Care Sector | 1 | 2016 | 26 | 0.120 |
Why?
|
| Poisson Distribution | 1 | 2016 | 78 | 0.120 |
Why?
|
| MicroRNAs | 2 | 2024 | 701 | 0.120 |
Why?
|
| Action Potentials | 1 | 2019 | 510 | 0.120 |
Why?
|
| Death Certificates | 1 | 2016 | 32 | 0.120 |
Why?
|
| Ventricular Function, Left | 1 | 2019 | 541 | 0.120 |
Why?
|
| Antipsychotic Agents | 1 | 2018 | 214 | 0.120 |
Why?
|
| Diet | 2 | 2021 | 1285 | 0.120 |
Why?
|
| Adaptive Immunity | 2 | 2019 | 169 | 0.110 |
Why?
|
| Exercise Tolerance | 1 | 2018 | 283 | 0.110 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 460 | 0.110 |
Why?
|
| Cystic Fibrosis | 1 | 2025 | 1162 | 0.110 |
Why?
|
| Transcription, Genetic | 2 | 2016 | 1496 | 0.110 |
Why?
|
| Drug Administration Schedule | 2 | 2014 | 784 | 0.110 |
Why?
|
| Pandemics | 2 | 2022 | 1698 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 386 | 0.110 |
Why?
|
| Heart Rate | 1 | 2019 | 857 | 0.110 |
Why?
|
| Commerce | 1 | 2016 | 79 | 0.110 |
Why?
|
| Acetylcysteine | 1 | 2016 | 139 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 380 | 0.110 |
Why?
|
| Streptomycin | 1 | 2014 | 18 | 0.110 |
Why?
|
| Cecum | 1 | 2014 | 37 | 0.110 |
Why?
|
| Hypoglycemic Agents | 1 | 2024 | 1391 | 0.110 |
Why?
|
| Mass Screening | 2 | 2018 | 1357 | 0.110 |
Why?
|
| Patch Tests | 3 | 2021 | 58 | 0.110 |
Why?
|
| International Classification of Diseases | 1 | 2016 | 147 | 0.110 |
Why?
|
| Drug Evaluation | 1 | 2014 | 79 | 0.110 |
Why?
|
| Metals | 1 | 2016 | 142 | 0.110 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2025 | 276 | 0.110 |
Why?
|
| Glucocorticoids | 2 | 2020 | 535 | 0.110 |
Why?
|
| Enterococcus faecium | 2 | 2025 | 22 | 0.110 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2014 | 48 | 0.110 |
Why?
|
| Cells, Cultured | 7 | 2013 | 4156 | 0.110 |
Why?
|
| Apoptosis | 4 | 2005 | 2430 | 0.110 |
Why?
|
| Sex Factors | 2 | 2021 | 2115 | 0.100 |
Why?
|
| Child | 6 | 2026 | 22712 | 0.100 |
Why?
|
| Environmental Monitoring | 2 | 2014 | 379 | 0.100 |
Why?
|
| Metallurgy | 1 | 2014 | 9 | 0.100 |
Why?
|
| Heart Diseases | 1 | 2017 | 350 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 758 | 0.100 |
Why?
|
| Haplotypes | 4 | 2010 | 490 | 0.100 |
Why?
|
| Israel | 1 | 2014 | 46 | 0.100 |
Why?
|
| CD40 Antigens | 1 | 2014 | 90 | 0.100 |
Why?
|
| Population Surveillance | 3 | 2009 | 485 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2014 | 331 | 0.100 |
Why?
|
| Colorado | 4 | 2020 | 4579 | 0.100 |
Why?
|
| Insulin | 1 | 2024 | 2507 | 0.100 |
Why?
|
| Genetic Markers | 3 | 2021 | 332 | 0.100 |
Why?
|
| B-Lymphocytes | 1 | 2019 | 877 | 0.100 |
Why?
|
| Prednisone | 1 | 2014 | 222 | 0.100 |
Why?
|
| Oxidative Stress | 3 | 2016 | 1341 | 0.100 |
Why?
|
| Occupational Health Services | 1 | 2013 | 37 | 0.100 |
Why?
|
| Teaching | 1 | 2016 | 240 | 0.100 |
Why?
|
| Models, Theoretical | 2 | 2014 | 582 | 0.100 |
Why?
|
| Imidazoles | 1 | 2014 | 254 | 0.100 |
Why?
|
| Phagocytosis | 1 | 2015 | 299 | 0.100 |
Why?
|
| Mice, Transgenic | 3 | 2026 | 2192 | 0.100 |
Why?
|
| Pulmonary Gas Exchange | 2 | 2004 | 119 | 0.100 |
Why?
|
| Myocardial Infarction | 1 | 2021 | 1211 | 0.100 |
Why?
|
| Liver | 1 | 2021 | 1893 | 0.100 |
Why?
|
| Enzyme Activation | 1 | 2014 | 768 | 0.100 |
Why?
|
| Nickel | 1 | 2013 | 64 | 0.090 |
Why?
|
| CTLA-4 Antigen | 1 | 2013 | 104 | 0.090 |
Why?
|
| Membrane Proteins | 2 | 2020 | 1169 | 0.090 |
Why?
|
| NF-kappa B | 2 | 2014 | 662 | 0.090 |
Why?
|
| MAP Kinase Signaling System | 1 | 2014 | 311 | 0.090 |
Why?
|
| Industry | 2 | 2011 | 43 | 0.090 |
Why?
|
| o-Phthalaldehyde | 1 | 2012 | 3 | 0.090 |
Why?
|
| Static Electricity | 1 | 2012 | 113 | 0.090 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 2013 | 73 | 0.090 |
Why?
|
| Linkage Disequilibrium | 2 | 2010 | 249 | 0.090 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 207 | 0.090 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2013 | 162 | 0.090 |
Why?
|
| Infliximab | 1 | 2012 | 111 | 0.090 |
Why?
|
| Ceftriaxone | 1 | 2012 | 21 | 0.090 |
Why?
|
| Societies, Medical | 3 | 2025 | 893 | 0.090 |
Why?
|
| Ciprofloxacin | 1 | 2012 | 26 | 0.090 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2019 | 691 | 0.090 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2012 | 163 | 0.090 |
Why?
|
| Risk Assessment | 4 | 2020 | 3686 | 0.090 |
Why?
|
| Epidermis | 1 | 2012 | 157 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 1048 | 0.090 |
Why?
|
| Amino Acid Substitution | 1 | 2012 | 304 | 0.090 |
Why?
|
| Mutation | 3 | 2025 | 4104 | 0.090 |
Why?
|
| DNA | 3 | 2016 | 1467 | 0.080 |
Why?
|
| Treatment Outcome | 5 | 2024 | 11731 | 0.080 |
Why?
|
| Gene Frequency | 3 | 2010 | 481 | 0.080 |
Why?
|
| Psoriasis | 1 | 2012 | 112 | 0.080 |
Why?
|
| Receptors, Cell Surface | 3 | 2020 | 377 | 0.080 |
Why?
|
| Metabolomics | 3 | 2023 | 727 | 0.080 |
Why?
|
| Surveys and Questionnaires | 4 | 2021 | 6079 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 2 | 2011 | 1054 | 0.080 |
Why?
|
| Diarrhea | 1 | 2012 | 194 | 0.080 |
Why?
|
| Interleukins | 1 | 2012 | 248 | 0.080 |
Why?
|
| Forced Expiratory Flow Rates | 1 | 2010 | 10 | 0.080 |
Why?
|
| fas Receptor | 2 | 2008 | 92 | 0.080 |
Why?
|
| Endocytosis | 1 | 1991 | 168 | 0.080 |
Why?
|
| Trigeminal Nerve Injuries | 2 | 2020 | 3 | 0.080 |
Why?
|
| Genes, MHC Class II | 1 | 2010 | 76 | 0.080 |
Why?
|
| Occupations | 2 | 2019 | 51 | 0.080 |
Why?
|
| Phosphorylation | 1 | 2014 | 1735 | 0.080 |
Why?
|
| Sulfasalazine | 1 | 2009 | 22 | 0.080 |
Why?
|
| Up-Regulation | 3 | 2008 | 853 | 0.080 |
Why?
|
| Diagnostic Errors | 1 | 2011 | 177 | 0.080 |
Why?
|
| Hospitalization | 1 | 2020 | 2443 | 0.080 |
Why?
|
| Antigens | 2 | 2021 | 347 | 0.070 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2009 | 28 | 0.070 |
Why?
|
| Exercise Test | 2 | 2003 | 635 | 0.070 |
Why?
|
| Virulence | 2 | 2025 | 280 | 0.070 |
Why?
|
| Homozygote | 2 | 2007 | 199 | 0.070 |
Why?
|
| Uveitis | 1 | 2010 | 149 | 0.070 |
Why?
|
| Multivariate Analysis | 3 | 2020 | 1540 | 0.070 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2008 | 23 | 0.070 |
Why?
|
| Epigenesis, Genetic | 2 | 2025 | 687 | 0.070 |
Why?
|
| Animals, Laboratory | 1 | 2008 | 21 | 0.070 |
Why?
|
| HLA-D Antigens | 1 | 2008 | 30 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1991 | 624 | 0.070 |
Why?
|
| Inflammation | 5 | 2023 | 2881 | 0.070 |
Why?
|
| Butyrophilins | 1 | 2007 | 5 | 0.070 |
Why?
|
| Time Factors | 3 | 2019 | 7186 | 0.070 |
Why?
|
| Eye Diseases | 2 | 2020 | 94 | 0.070 |
Why?
|
| Linear Models | 2 | 2021 | 854 | 0.070 |
Why?
|
| Antigen Presentation | 2 | 2005 | 205 | 0.070 |
Why?
|
| CD57 Antigens | 1 | 2007 | 18 | 0.060 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2008 | 187 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2008 | 307 | 0.060 |
Why?
|
| Prevalence | 2 | 2011 | 2838 | 0.060 |
Why?
|
| Antigens, CD | 2 | 2008 | 555 | 0.060 |
Why?
|
| Total Lung Capacity | 1 | 2006 | 29 | 0.060 |
Why?
|
| Glutamate-Cysteine Ligase | 1 | 2006 | 20 | 0.060 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2007 | 178 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2025 | 8011 | 0.060 |
Why?
|
| Flow Cytometry | 3 | 2023 | 1173 | 0.060 |
Why?
|
| Protein Binding | 1 | 2012 | 2283 | 0.060 |
Why?
|
| Cell Separation | 2 | 2023 | 307 | 0.060 |
Why?
|
| B7-2 Antigen | 2 | 2017 | 27 | 0.060 |
Why?
|
| Netherlands | 2 | 2019 | 82 | 0.060 |
Why?
|
| Cell Line | 5 | 2013 | 2882 | 0.060 |
Why?
|
| Mice, Knockout | 2 | 2026 | 3129 | 0.060 |
Why?
|
| Chemical Industry | 1 | 2005 | 9 | 0.060 |
Why?
|
| Pesticides | 1 | 2025 | 63 | 0.060 |
Why?
|
| Peptides | 2 | 2026 | 999 | 0.060 |
Why?
|
| Cytoskeletal Proteins | 1 | 2025 | 156 | 0.050 |
Why?
|
| Pyrrolidines | 1 | 2025 | 126 | 0.050 |
Why?
|
| Nuclear Warfare | 1 | 2004 | 10 | 0.050 |
Why?
|
| Protein Structure, Secondary | 1 | 2005 | 369 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 1991 | 1325 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2025 | 392 | 0.050 |
Why?
|
| Endotoxemia | 1 | 2025 | 87 | 0.050 |
Why?
|
| Ferritins | 1 | 2004 | 69 | 0.050 |
Why?
|
| Anastomotic Leak | 1 | 2024 | 44 | 0.050 |
Why?
|
| HLA-DRB3 Chains | 1 | 2003 | 2 | 0.050 |
Why?
|
| HLA-DRB5 Chains | 1 | 2003 | 2 | 0.050 |
Why?
|
| HLA-DRB4 Chains | 1 | 2003 | 6 | 0.050 |
Why?
|
| Molecular Docking Simulation | 1 | 2024 | 124 | 0.050 |
Why?
|
| Dysbiosis | 1 | 2025 | 187 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 5431 | 0.050 |
Why?
|
| CX3C Chemokine Receptor 1 | 1 | 2023 | 20 | 0.050 |
Why?
|
| Sutures | 1 | 2024 | 64 | 0.050 |
Why?
|
| Moths | 1 | 2024 | 52 | 0.050 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2003 | 57 | 0.050 |
Why?
|
| Genomics | 2 | 2022 | 842 | 0.050 |
Why?
|
| HLA-DR alpha-Chains | 1 | 2023 | 5 | 0.050 |
Why?
|
| Laparotomy | 1 | 2024 | 112 | 0.050 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2004 | 168 | 0.050 |
Why?
|
| Larva | 1 | 2024 | 244 | 0.050 |
Why?
|
| Phycobilins | 1 | 2023 | 4 | 0.050 |
Why?
|
| Phycocyanin | 1 | 2023 | 4 | 0.050 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2025 | 328 | 0.050 |
Why?
|
| Endothelium | 1 | 2023 | 119 | 0.050 |
Why?
|
| Decision Making | 1 | 2010 | 980 | 0.050 |
Why?
|
| Reference Standards | 1 | 2023 | 178 | 0.050 |
Why?
|
| Cobalt | 1 | 2002 | 53 | 0.050 |
Why?
|
| Tomography, Optical Coherence | 1 | 2024 | 272 | 0.050 |
Why?
|
| Aluminum | 1 | 2002 | 43 | 0.050 |
Why?
|
| Thorax | 1 | 2022 | 50 | 0.050 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2023 | 102 | 0.050 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2025 | 356 | 0.050 |
Why?
|
| Granuloma, Respiratory Tract | 1 | 2002 | 13 | 0.050 |
Why?
|
| RNA, Messenger | 3 | 2024 | 2833 | 0.050 |
Why?
|
| Immunity, Active | 1 | 2002 | 8 | 0.050 |
Why?
|
| Iron Metabolism Disorders | 1 | 2021 | 6 | 0.040 |
Why?
|
| Myosins | 1 | 2022 | 136 | 0.040 |
Why?
|
| Potassium, Dietary | 1 | 2021 | 12 | 0.040 |
Why?
|
| Whole Body Imaging | 1 | 2021 | 29 | 0.040 |
Why?
|
| DNA Probes, HLA | 1 | 2001 | 1 | 0.040 |
Why?
|
| Diet Surveys | 1 | 2021 | 91 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2025 | 510 | 0.040 |
Why?
|
| Indoles | 1 | 2025 | 501 | 0.040 |
Why?
|
| Epitopes | 1 | 2003 | 485 | 0.040 |
Why?
|
| Dietary Fiber | 1 | 2021 | 59 | 0.040 |
Why?
|
| Cells | 1 | 2021 | 25 | 0.040 |
Why?
|
| Antigens, Fungal | 1 | 2021 | 28 | 0.040 |
Why?
|
| Bronchiolitis | 1 | 2002 | 87 | 0.040 |
Why?
|
| Ligands | 1 | 2023 | 676 | 0.040 |
Why?
|
| Eosinophil Cationic Protein | 1 | 2021 | 9 | 0.040 |
Why?
|
| Enzyme-Linked Immunospot Assay | 2 | 2011 | 37 | 0.040 |
Why?
|
| HLA-DR3 Antigen | 1 | 2021 | 76 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2016 | 848 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2004 | 725 | 0.040 |
Why?
|
| Hybridomas | 1 | 2021 | 234 | 0.040 |
Why?
|
| CD55 Antigens | 1 | 2021 | 29 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2022 | 284 | 0.040 |
Why?
|
| CD28 Antigens | 2 | 2013 | 58 | 0.040 |
Why?
|
| Chemokine CXCL9 | 1 | 2021 | 38 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2021 | 130 | 0.040 |
Why?
|
| Mining | 1 | 2001 | 36 | 0.040 |
Why?
|
| Minimal Clinically Important Difference | 1 | 2021 | 31 | 0.040 |
Why?
|
| Click Chemistry | 1 | 2021 | 53 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 851 | 0.040 |
Why?
|
| Bone Cements | 1 | 2021 | 39 | 0.040 |
Why?
|
| Chi-Square Distribution | 3 | 2011 | 529 | 0.040 |
Why?
|
| Fungal Proteins | 1 | 2021 | 145 | 0.040 |
Why?
|
| Th17 Cells | 1 | 2021 | 101 | 0.040 |
Why?
|
| Radiography | 1 | 2003 | 846 | 0.040 |
Why?
|
| Pharmaceutical Preparations | 1 | 2022 | 170 | 0.040 |
Why?
|
| CD11c Antigen | 1 | 2020 | 40 | 0.040 |
Why?
|
| Biomedical Engineering | 1 | 2020 | 29 | 0.040 |
Why?
|
| Serologic Tests | 1 | 2020 | 53 | 0.040 |
Why?
|
| Lymphadenopathy | 1 | 2020 | 8 | 0.040 |
Why?
|
| Mediastinum | 1 | 2020 | 23 | 0.040 |
Why?
|
| Fatigue Syndrome, Chronic | 1 | 2020 | 19 | 0.040 |
Why?
|
| Textiles | 1 | 2020 | 22 | 0.040 |
Why?
|
| Hypercalcemia | 1 | 2020 | 22 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 86 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2020 | 118 | 0.040 |
Why?
|
| Oxygen | 2 | 2022 | 995 | 0.040 |
Why?
|
| Receptors, Fc | 1 | 2020 | 55 | 0.040 |
Why?
|
| Self-Help Devices | 1 | 2020 | 24 | 0.040 |
Why?
|
| Stochastic Processes | 1 | 2020 | 71 | 0.040 |
Why?
|
| Cryosurgery | 1 | 2020 | 47 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 2020 | 85 | 0.040 |
Why?
|
| Intersectoral Collaboration | 1 | 2020 | 64 | 0.040 |
Why?
|
| T-Box Domain Proteins | 1 | 2020 | 106 | 0.040 |
Why?
|
| Oleic Acids | 1 | 2019 | 12 | 0.040 |
Why?
|
| Staphylococcal Infections | 1 | 2024 | 391 | 0.040 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2020 | 64 | 0.040 |
Why?
|
| Fractals | 1 | 2019 | 8 | 0.040 |
Why?
|
| Mobility Limitation | 1 | 2020 | 66 | 0.040 |
Why?
|
| Prostheses and Implants | 1 | 2021 | 141 | 0.040 |
Why?
|
| Radionuclide Imaging | 1 | 2019 | 113 | 0.040 |
Why?
|
| Models, Animal | 1 | 2021 | 392 | 0.040 |
Why?
|
| Receptors, Complement 3d | 1 | 2020 | 142 | 0.040 |
Why?
|
| Autoantigens | 1 | 2022 | 429 | 0.040 |
Why?
|
| Amino Acid Sequence | 3 | 2013 | 2158 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2020 | 151 | 0.040 |
Why?
|
| Tertiary Lymphoid Structures | 1 | 2019 | 7 | 0.040 |
Why?
|
| Animal Feed | 1 | 2019 | 54 | 0.040 |
Why?
|
| Alkaline Phosphatase | 1 | 2020 | 145 | 0.040 |
Why?
|
| Chemokine CXCL13 | 1 | 2019 | 15 | 0.040 |
Why?
|
| Pulmonary Surfactant-Associated Protein A | 1 | 2019 | 29 | 0.040 |
Why?
|
| Pulmonary Medicine | 1 | 2020 | 79 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2021 | 248 | 0.040 |
Why?
|
| Receptors, Immunologic | 1 | 2020 | 208 | 0.040 |
Why?
|
| Pulmonary Surfactant-Associated Protein C | 1 | 2019 | 45 | 0.040 |
Why?
|
| GTPase-Activating Proteins | 1 | 2019 | 82 | 0.040 |
Why?
|
| Systole | 1 | 2019 | 178 | 0.040 |
Why?
|
| RNA, Bacterial | 1 | 2020 | 189 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2019 | 215 | 0.040 |
Why?
|
| Exoribonucleases | 1 | 2019 | 45 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2022 | 750 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2013 | 264 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 442 | 0.040 |
Why?
|
| Endosonography | 1 | 2020 | 158 | 0.040 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2019 | 118 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2023 | 576 | 0.040 |
Why?
|
| Electric Countershock | 1 | 2019 | 128 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 1991 | 2464 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2022 | 586 | 0.030 |
Why?
|
| Interleukin-2 | 2 | 2013 | 437 | 0.030 |
Why?
|
| Autoimmunity | 1 | 2004 | 935 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 1999 | 333 | 0.030 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2019 | 117 | 0.030 |
Why?
|
| Benchmarking | 1 | 2019 | 189 | 0.030 |
Why?
|
| Bile Acids and Salts | 1 | 2019 | 164 | 0.030 |
Why?
|
| Delphi Technique | 1 | 2020 | 332 | 0.030 |
Why?
|
| Creatinine | 1 | 2020 | 510 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2022 | 1103 | 0.030 |
Why?
|
| Receptor, Parathyroid Hormone, Type 1 | 1 | 2017 | 3 | 0.030 |
Why?
|
| DNA Helicases | 1 | 2019 | 143 | 0.030 |
Why?
|
| Reoperation | 1 | 2021 | 631 | 0.030 |
Why?
|
| Telomere-Binding Proteins | 1 | 2019 | 119 | 0.030 |
Why?
|
| Caenorhabditis elegans | 1 | 2021 | 337 | 0.030 |
Why?
|
| Janus Kinase 1 | 1 | 2017 | 26 | 0.030 |
Why?
|
| New York City | 1 | 2017 | 89 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2004 | 2032 | 0.030 |
Why?
|
| High Mobility Group Proteins | 1 | 2017 | 45 | 0.030 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2017 | 45 | 0.030 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2019 | 231 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2002 | 1063 | 0.030 |
Why?
|
| Chromosome Mapping | 2 | 2004 | 510 | 0.030 |
Why?
|
| Forecasting | 1 | 2019 | 392 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2023 | 872 | 0.030 |
Why?
|
| RNA Splicing Factors | 1 | 2017 | 65 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2020 | 502 | 0.030 |
Why?
|
| Epigenomics | 1 | 2017 | 114 | 0.030 |
Why?
|
| Telomerase | 1 | 2019 | 249 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2025 | 11863 | 0.030 |
Why?
|
| Echocardiography | 1 | 2020 | 656 | 0.030 |
Why?
|
| Base Sequence | 2 | 2014 | 2191 | 0.030 |
Why?
|
| Mucin-5B | 1 | 2019 | 234 | 0.030 |
Why?
|
| Vitamin D | 1 | 2020 | 400 | 0.030 |
Why?
|
| Cross-Sectional Studies | 2 | 2011 | 5883 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 824 | 0.030 |
Why?
|
| Poverty | 1 | 2020 | 530 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2019 | 653 | 0.030 |
Why?
|
| Sleep Wake Disorders | 1 | 2020 | 309 | 0.030 |
Why?
|
| Brain Diseases | 1 | 1997 | 153 | 0.030 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2020 | 300 | 0.030 |
Why?
|
| Defibrillators, Implantable | 1 | 2019 | 382 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 1327 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2017 | 233 | 0.030 |
Why?
|
| Hospitals | 1 | 2020 | 733 | 0.030 |
Why?
|
| Chronic Pain | 1 | 2020 | 292 | 0.030 |
Why?
|
| Mitochondrial Proteins | 1 | 2017 | 263 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2017 | 374 | 0.030 |
Why?
|
| Atherosclerosis | 1 | 2019 | 409 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 1661 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2022 | 1510 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2014 | 2931 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2021 | 826 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2017 | 460 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2017 | 431 | 0.030 |
Why?
|
| Software | 1 | 2019 | 693 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2017 | 437 | 0.030 |
Why?
|
| Calcium | 1 | 2020 | 1185 | 0.030 |
Why?
|
| Protective Devices | 1 | 2014 | 29 | 0.030 |
Why?
|
| United States Occupational Safety and Health Administration | 1 | 2013 | 6 | 0.020 |
Why?
|
| Health Personnel | 1 | 2020 | 748 | 0.020 |
Why?
|
| Heme Oxygenase-1 | 1 | 2014 | 74 | 0.020 |
Why?
|
| B7-1 Antigen | 1 | 2013 | 55 | 0.020 |
Why?
|
| Hematologic Tests | 1 | 2013 | 21 | 0.020 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2013 | 24 | 0.020 |
Why?
|
| Lymphokines | 1 | 2013 | 130 | 0.020 |
Why?
|
| Gene Transfer, Horizontal | 1 | 2013 | 35 | 0.020 |
Why?
|
| Peptide Library | 1 | 2013 | 95 | 0.020 |
Why?
|
| Drug Resistance, Microbial | 1 | 2013 | 70 | 0.020 |
Why?
|
| Etanercept | 1 | 2012 | 60 | 0.020 |
Why?
|
| Immunity | 1 | 2013 | 139 | 0.020 |
Why?
|
| Infusions, Parenteral | 1 | 2012 | 44 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2016 | 1087 | 0.020 |
Why?
|
| Phagocytes | 2 | 2004 | 81 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 2012 | 122 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2013 | 199 | 0.020 |
Why?
|
| Microscopy, Immunoelectron | 1 | 1991 | 43 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2012 | 177 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2024 | 2938 | 0.020 |
Why?
|
| Immunotoxins | 1 | 1991 | 55 | 0.020 |
Why?
|
| Hypertension | 1 | 2020 | 1266 | 0.020 |
Why?
|
| Mammals | 1 | 2013 | 293 | 0.020 |
Why?
|
| Ontario | 1 | 2011 | 96 | 0.020 |
Why?
|
| Program Development | 1 | 2013 | 370 | 0.020 |
Why?
|
| Keratinocytes | 1 | 2012 | 250 | 0.020 |
Why?
|
| Self Report | 1 | 2015 | 873 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2011 | 370 | 0.020 |
Why?
|
| Gold | 1 | 1991 | 116 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2019 | 2439 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2011 | 143 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2013 | 406 | 0.020 |
Why?
|
| Plasmids | 1 | 1991 | 379 | 0.020 |
Why?
|
| Regeneration | 1 | 2012 | 197 | 0.020 |
Why?
|
| Risk | 2 | 2004 | 912 | 0.020 |
Why?
|
| Japan | 1 | 2010 | 145 | 0.020 |
Why?
|
| Depression | 1 | 2020 | 1561 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2013 | 328 | 0.020 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2010 | 80 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2012 | 627 | 0.020 |
Why?
|
| Binding Sites | 1 | 2013 | 1333 | 0.020 |
Why?
|
| CD3 Complex | 1 | 2010 | 111 | 0.020 |
Why?
|
| United Kingdom | 1 | 2010 | 338 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 2009 | 160 | 0.020 |
Why?
|
| Transfection | 1 | 1991 | 940 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2010 | 202 | 0.020 |
Why?
|
| 4-1BB Ligand | 1 | 2008 | 7 | 0.020 |
Why?
|
| Blood Proteins | 1 | 2011 | 249 | 0.020 |
Why?
|
| Demography | 1 | 2009 | 288 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2013 | 949 | 0.020 |
Why?
|
| Hypertension, Pulmonary | 1 | 2020 | 1980 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 1311 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2009 | 322 | 0.020 |
Why?
|
| Codon | 1 | 2007 | 94 | 0.020 |
Why?
|
| Adjuvants, Immunologic | 1 | 2008 | 246 | 0.020 |
Why?
|
| Fibrosis | 1 | 2009 | 550 | 0.020 |
Why?
|
| Obesity | 1 | 2020 | 3085 | 0.020 |
Why?
|
| Cell Survival | 1 | 2009 | 1099 | 0.020 |
Why?
|
| Transcription Factor AP-1 | 1 | 2006 | 79 | 0.010 |
Why?
|
| Gene Dosage | 1 | 2006 | 148 | 0.010 |
Why?
|
| Fibroblasts | 1 | 1991 | 1036 | 0.010 |
Why?
|
| Catalytic Domain | 1 | 2006 | 234 | 0.010 |
Why?
|
| Caspase 8 | 1 | 2005 | 47 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2005 | 277 | 0.010 |
Why?
|
| RNA Precursors | 1 | 2006 | 156 | 0.010 |
Why?
|
| Free Radical Scavengers | 1 | 2005 | 82 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2005 | 164 | 0.010 |
Why?
|
| Metalloporphyrins | 1 | 2005 | 66 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2005 | 381 | 0.010 |
Why?
|
| Nuclear Family | 1 | 2004 | 52 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2004 | 44 | 0.010 |
Why?
|
| Radioisotopes | 1 | 2004 | 37 | 0.010 |
Why?
|
| Caspases | 1 | 2005 | 232 | 0.010 |
Why?
|
| Species Specificity | 1 | 2005 | 574 | 0.010 |
Why?
|
| Infant | 1 | 2017 | 10101 | 0.010 |
Why?
|
| Reference Values | 1 | 2004 | 798 | 0.010 |
Why?
|
| Kinetics | 1 | 2006 | 1630 | 0.010 |
Why?
|
| Rats | 1 | 1991 | 5616 | 0.010 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 2002 | 23 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2002 | 121 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2002 | 183 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2006 | 750 | 0.010 |
Why?
|
| Incidence | 1 | 2008 | 2892 | 0.010 |
Why?
|
| Utah | 1 | 2001 | 81 | 0.010 |
Why?
|
| Oximetry | 1 | 2001 | 126 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2004 | 668 | 0.010 |
Why?
|
| Tetanus Toxoid | 1 | 2000 | 34 | 0.010 |
Why?
|
| Bromodeoxyuridine | 1 | 2000 | 79 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 2000 | 62 | 0.010 |
Why?
|
| Volatilization | 1 | 2000 | 52 | 0.010 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2000 | 100 | 0.010 |
Why?
|
| Scattering, Radiation | 1 | 2000 | 103 | 0.010 |
Why?
|
| HLA-DP alpha-Chains | 1 | 1999 | 4 | 0.010 |
Why?
|
| Genetic Carrier Screening | 1 | 1999 | 32 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2000 | 131 | 0.010 |
Why?
|
| Dimerization | 1 | 1999 | 194 | 0.010 |
Why?
|
| Acute Disease | 1 | 2002 | 1031 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2006 | 1746 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2000 | 330 | 0.010 |
Why?
|
| Equipment Design | 1 | 2000 | 530 | 0.010 |
Why?
|
| Cell Movement | 1 | 2002 | 965 | 0.010 |
Why?
|
| Skin | 1 | 2002 | 758 | 0.010 |
Why?
|
| Light | 1 | 2000 | 411 | 0.010 |
Why?
|